Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
145 hedge funds and large institutions have $792M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 54 increasing their positions, 43 reducing their positions, and 15 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 43
21% more call options, than puts
Call options by funds: $264K | Put options by funds: $218K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
1% less funds holding
Funds holding: 146 → 145 (-1)
12% less capital invested
Capital invested by funds: $897M → $792M (-$104M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$21.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.8M |
| 3 |
AC
Armistice Capital
New York
|
+$6.58M |
| 4 |
Morgan Stanley
New York
|
+$6.25M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$5.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$21.1M |
| 2 |
Goldman Sachs
New York
|
-$13.4M |
| 3 |
JFG
Jefferies Financial Group
New York
|
-$10.7M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$10.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.43M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
TD Asset Management
Toronto,
Ontario, Canada
| – | -$637K | -41,200 | Closed |
|
|
FRM
152
Fox Run Management
Greenwich,
Connecticut
| – | -$390K | -25,248 | Closed |
|
|
EGM
153
Engineers Gate Manager
New York
| – | -$372K | -24,079 | Closed |
|
|
BCM
154
Bayesian Capital Management
Brooklyn,
New York
| – | -$346K | -22,411 | Closed |
|
155
Alyeska Investment Group
Chicago,
Illinois
| – | -$315K | -20,400 | Closed |
|
|
AG
156
Algert Global
San Francisco,
California
| – | -$239K | -15,492 | Closed |
|
157
Lazard Asset Management
New York
| – | -$130K | -8,421 | Closed |
|
|
TWA
158
TCI Wealth Advisors
Tucson,
Arizona
| – | -$4.48K | -290 | Closed |
|
|
EI
159
Ellevest Inc
New York
| – | -$2.49K | -161 | Closed |
|
DCPH Hedge Fund Activity: Q2 2023 in Review
145 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q2 2023, worth a combined $792M — down 12% from $897M a quarter earlier.
Fund positioning in DCPH was balanced in Q2 2023: 15 funds opened new positions, 15 closed out, 54 added to existing stakes and 43 trimmed.
The largest buyer was Deerfield Management, adding an estimated $21.3M. The largest seller was Deep Track Capital, exiting entirely with an estimated $21.1M sold.
- 145 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q2 2023, down from 146 in Q1 2023.
- Funds reported $792M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q2 2023, down 12% quarter-over-quarter.
- 15 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q2 2023 and 15 closed out, a net change of 0 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q2 2023 was Deerfield Management, an estimated $21.3M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q2 2023 was Deep Track Capital, an estimated $21.1M sold.
Based on aggregated 13F filings for Q2 2023.